Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen
Christina Peters,
Angela Bruno,
Carmelo Rizzari,
Alessandra Brescianini,
Arend von Stackelberg,
Christin Linderkamp,
Yi Zeng,
Gerhard Zugmaier,
Franco Locatelli
Affiliations
Christina Peters
St. Anna Children’s Hospital, St. Anna Children’s Cancer Research Institute, University Vienna, Vienna
Angela Bruno
Amgen Italia, Milan
Carmelo Rizzari
MBBM Foundation, University of Milano-Bicocca, Monza
Alessandra Brescianini
Amgen (Europe) GmbH, Rotkreuz
Arend von Stackelberg
Charité Universitaetsmedizin CVK Berlin, Berlin
Christin Linderkamp
Medizinische Hochschule Hannover, Hannover
Yi Zeng
Amgen Inc., Thousand Oaks, CA
Gerhard Zugmaier
Amgen Research (Munich) GmbH, Munich
Franco Locatelli
IRCCS Ospedale Pediatrico Bambino Gesù and Catholic University of the Sacred Heart, Rome
